[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631100":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":50,"collaborators":26,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":26,"enrollmentInfo":62,"targetDuration":26,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":81,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Ewha Womans University Mokdong Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Rhythm-guided antithrombotic strategy","EXPERIMENTAL","Discontinuation of oral anticoagulation with continuation of single antiplatelet therapy after atrial fibrillation ablation.",[13],"Drug: Single antiplatelet therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Continuous oral anticoagulation","ACTIVE_COMPARATOR","Continuation of oral anticoagulation therapy after atrial fibrillation ablation in patients with prior drug-eluting stent implantation.",[19],"Drug: Oral anticoagulation",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Oral anticoagulation","Non-vitamin K antagonist oral anticoagulant therapy used for stroke prevention in atrial fibrillation.",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Single antiplatelet therapy","Single antiplatelet therapy such as aspirin or a P2Y12 inhibitor.",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Yeji Kim, MD, PhD","CONTACT","+82-10-8680-9542","lexie6169@gmail.com",[38],{"facility":5,"status":26,"city":39,"state":26,"zip":40,"country":41,"countryCode":26,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Seoul","07804","South Korea",{"type":43,"coordinates":44},"Point",[45,46],126.9784,37.566,{"lat":46,"lon":45},[49],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"type":51,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100631100","phase-4-optia-af-trial-rhythm-guided-antithrombotic-strategy-after-af-ablation-100631100",false,"NCT07496281","OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation","OPTIA-AF Trial: A Randomized Study of Rhythm-Guided Antithrombotic Strategy After Atrial Fibrillation Ablation in Patients With Prior Drug-Eluting Stent Implantation","OPTIA-AF","1. Inclusion Criteria\n\n   * Participants must meet all of the following criteria:\n   * Age ≥18 years.\n   * Documented history of atrial fibrillation (paroxysmal or persistent).\n   * Successful catheter ablation for atrial fibrillation performed within the previous 3-6 months.\n   * Maintenance of sinus rhythm after ablation, confirmed by follow-up electrocardiography or rhythm monitoring.\n   * History of percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation.\n   * Completion of the recommended duration of dual antiplatelet therapy (DAPT) following PCI.\n   * Currently receiving oral anticoagulation therapy with a non-vitamin K antagonist oral anticoagulant (NOAC).\n   * Clinically stable and considered eligible for long-term antithrombotic therapy adjustment by the treating physician.\n   * Ability to understand the study procedures and provide written informed consent.\n2. Exclusion Criteria\n\n   * Participants will be excluded if any of the following criteria are present:\n   * Recurrent atrial fibrillation documented after the index ablation procedure requiring repeat ablation or antiarrhythmic escalation.\n   * Presence of mechanical heart valve or moderate-to-severe mitral stenosis.\n   * Indication for long-term anticoagulation independent of atrial fibrillation (e.g., venous thromboembolism, mechanical valve).\n   * Recent acute coronary syndrome or PCI within the past 3 months.\n   * Planned coronary revascularization or cardiac surgery.\n   * History of intracranial hemorrhage or other major bleeding that contraindicates antithrombotic therapy.\n   * Severe renal dysfunction (e.g., estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n   * Severe hepatic dysfunction associated with coagulopathy.\n   * Known hypersensitivity or contraindication to aspirin or NOAC therapy.\n   * Pregnancy or breastfeeding.\n   * Life expectancy less than 1 year due to non-cardiovascular comorbidities.\n   * Participation in another interventional clinical trial that may interfere with the study outcomes.","ALL","18 Years",{"count":63,"type":64},2,"ESTIMATED","INTERVENTIONAL",[67],"PHASE4","The OPTIA-AF trial is a prospective, multicenter randomized controlled trial designed to evaluate a rhythm-guided antithrombotic strategy in patients with atrial fibrillation (AF) who maintain durable sinus rhythm after catheter ablation and have a history of prior drug-eluting stent (DES) implantation. Current guidelines generally recommend long-term oral anticoagulation (OAC) in patients with AF, even after successful ablation, while antiplatelet therapy remains essential for prevention of coronary ischemic events following percutaneous coronary intervention.\n\nOPTIA-AF tests whether discontinuation of non-vitamin K antagonist oral anticoagulant (NOAC) therapy with transition to single antiplatelet therapy (SAPT) is non-inferior to continued NOAC therapy in patients who maintain sinus rhythm for at least 12 months after AF ablation. Participants will be randomized in a 1:1 ratio to either continued NOAC therapy or NOAC discontinuation with SAPT.\n\nThe primary endpoint is a 24-month composite net clinical outcome including ischemic stroke, systemic embolism, myocardial infarction, definite or probable stent thrombosis, cardiovascular death, and major bleeding.",[70,71,72],"Atrial Fibrillation (AF)","Coronary Artery Disease","Drug-eluting Stent",[74,75,23,76,28,77,78,79,80],"Atrial fibrillation ablation","Antithrombotic therapy","Non-vitamin K antagonist oral anticoagulant","Drug-eluting stent","Rhythm-guided strategy","Catheter ablation","Randomized controlled trial","NOT_YET_RECRUITING","2026-03-23",{"date":84,"type":85},"2026-03-27","ACTUAL",{"date":87,"type":64},"2027-03-01",{"date":89,"type":64},"2035-03-01",{"name":5,"class":6},1]